ESC 365 - Doctor Jawad Haider Butt

Speaker illustration

Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

Member of:

Heart Failure Association

Presentations Articles

Implantable cardioverter-defibrillator at least as effective in frail patients with nonischemic heart failure with reduced ejection fraction: extended follow-up of the DANISH trial

Event: Heart Failure 2025

Topic: Implantable Cardioverter-Defibrillator (ICD)

Session: Arrhythmias and devices

Red cell distribution width (RDW) and outcomes in HFmrEF/HFpEF: Insights from FINEARTS-HF

Event: Heart Failure 2025

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Personalised approaches to HFpEF: diagnostic tools, biomarkers, and prognostic insights

Anthropometric measures and long-term mortality in heart failure with reduced ejection: debunking the obesity paradox

Event: ESC Congress 2024

Topic: Epidemiology, Prognosis, Outcome

Session: From obesity to prediction of outcomes in acute heart failure

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Drug therapy for heart failure: what is new?

New york heart association functional class does not modify the effect of an implantable cardioverter-defibrillator in nonischemic heart failure with reduced ejection fraction: a DANISH substudy

Event: Heart Failure 2024

Topic: Implantable Cardioverter-Defibrillator (ICD)

Session: Arrhythmias in heart failure

Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

Event: ESC Congress 2023

Topic: Treatment

Session: State-of-the art treatment of HFmrEF and HFpEF in 2023

Dapagliflozin and PAD in HF

Event: Heart Failure 2023

Topic: Clinical

Session: Late breaking clinical trials

Kidney outcomes in heart failure trials: does endpoint definition matter?

Event: Heart Failure 2023

Topic: Treatment

Session: Chronic heart failure - treatment 5

Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial

Event: ESC Congress 2022

Topic: Comorbidities

Session: How to treat HFpEF in 2022 and beyond

Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

Event: Heart Failure 2022

Topic: Pharmacotherapy

Session: Young Investigator Award: clinical research

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources